CD9 and malignant glioma: Finally, American researchers reported that the decreased release of circulating CD9+/GFAP+/SVN+ and CD9+/SVN+ exosomes in patients with malignant glioma, receiving anti-survivin immunotherapy, may be correlated with longer progression free survival [55].